Although our cohort includes a substantial proportion of obese patients (24.5%), we did not observe a survival benefit in obese patients; however, the number of PD-L1 positive ICI-monotherapy treated patients in our study may have been insufficient to detect a benefit of obesity. This evidence concerns the gene CD274 and obesity disorder.